Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 11INDUSTRY 3NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 48Myeloid 25Lymphoid 7Breast 6Tumor-Agnostic 3Genitourinary 3Plasma cell 2Thoracic 1Gastrointestinal 1CNS 1

Conditions

Prostatic Neoplasms 3

Interventions

pembrolizumab 164Prednisone 130enzalutamide 127Docetaxel 122Abiraterone Acetate 95Nivolumab 93Gemcitabine 71Sunitinib 67atezolizumab 50abiraterone 50Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48Cisplatin 48radium Ra 223 dichloride 39Sorafenib 39darolutamide 38apalutamide 38Ipilimumab 38Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32cabozantinib 31avelumab 31pazopanib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Dasatinib × Genitourinary × Clear all
NCT00744497 2016-10-17

READY

Bristol-Myers Squibb

Phase 3 Completed
1,930 enrolled 23 charts
Genitourinary

Prostatic Neoplasms

NCT00439270 2014-03-28

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

Bristol-Myers Squibb

Phase 1/2 Completed
49 enrolled 25 charts
Genitourinary

Prostatic Neoplasms

NCT00385580 2013-04-30

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

Bristol-Myers Squibb

Phase 2 Completed
94 enrolled 50 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡